Borosil Scientific Limited — PPTs, 14-02-2025: Investor Presentation

**Financial Highlights**: Borosil Scientific reported a net sales increase to ₹101.5 Cr for Q3FY25, reflecting a 1.5% year-on-year growth. However, EBITDA decreased by 7.3% to ₹13.7 Cr, influenced by temporary production reductions in the Pharma Packaging segment, which affected margins. Year-to-date sales show an improvement of 10.2% compared to the previous year.

**Strategic Initiatives and Growth Drivers**: The company continues to develop its scientific offerings, having recently expanded its lab equipment and consumables range. Initiatives include growing the sales team and diversifying the product portfolio, particularly through its acquisition of Goel Scientific.

**Business Developments**: Borosil's financial performance in Q3 reflects its robust presence in laboratory glassware, with gains noted in lab consumables. The company plans to enhance its market position through new product development and expansion into international markets.

**Market Position and Competitive Advantage**: With a market cap of approximately ₹1407 Cr, Borosil is positioned as a leader in laboratory glassware and scientific instruments in India. Its commitment to quality and innovation bolsters its reputation in both domestic and global markets.

**Investor Implications**: Investors should monitor Borosil's performance closely, particularly as the company leverages its strengths to improve sales and EBITDA in upcoming quarters. The focus on scientific product innovation and market expansion offers potential for sustained growth.